PRG 2311
Alternative Names: PRG-2311Latest Information Update: 19 Jul 2024
At a glance
- Originator Pregene ShenZhen Biotechnology
- Class CAR-T cell therapies; Gene therapies; Immunotherapies; Urologics
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Lupus nephritis
Most Recent Events
- 11 Jul 2024 Preclinical trials in Lupus nephritis in China (Parenteral), prior to July 2024
- 11 Jul 2024 Pregene ShenZhen Biotechnology in collaboration with Tongji Hospital plans a phase I trial for for Lupus nephritis (In volunteers) in China (NCT06497361)